Antibody responses to survivin and their clinical significance in patients with head and neck cancer

Head and Neck

Volumn 29, Issue 12, 2007, Pages 1128-1135

  Eto, Mayumi ^a   Kodama, Satoru ^a   Uemura, Naoki ^a   Suzuki, Masashi ^a  

^a OITA UNIVERSITY   (Japan)

Author keywords

Anti survivin antibody; Head and neck cancer; p53; SCC; Survivin

Indexed keywords

ANTIBODY; SURVIVIN; TUMOR ANTIGEN; TUMOR MARKER;

ADULT; AGED; ANTIBODY RESPONSE; ARTICLE; CANCER PATIENT; CONTROLLED STUDY; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEAD AND NECK CANCER; HUMAN; HUMORAL IMMUNITY; HYPOPHARYNX CANCER; LARYNX CANCER; MAJOR CLINICAL STUDY; MALE; NOSE CANCER; OROPHARYNX CANCER; PARANASAL SINUS CANCER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION;

AGED; ANTIBODIES; ANTIGENS, NEOPLASM; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; LYMPHATIC METASTASIS; MALE; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; NEOPLASM PROTEINS; SERPINS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 38048998545     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.20652     Document Type: Article

References (27)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106-130.
2. Thomas GR, Nadiminti H, Regalado J. Molecular predictors of clinical outcome in patients with head and neck squamous cell carcinoma. Int J Exp Pathol 2005;86:347-363.
3. Sahin U, Tureci OE, Schmitt H, et al. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci U S A 1995;92:11810-11813.
4. Old L, Chen YT. New paths in human cancer serology. J Exp Med 1998;187:1163-1167.
5. Angelopoulou K, Diamandis E, Sutherland DJA, Kellen JA, Bunting PS. Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers. Int J Cancer 1994;58:480-487.
6. LaCasse EC, Bairrd S, Korneluk RG, Mckenzie AE. The inhibitors of apoptosis (IAP) and their emerging role in cancer. Oncogene 1998;17:3247-3259.
7. Li F. Survivin study: what is the next wave. J Cell Physiol 2003;197:8-29.
8. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997;3:917-921.
9. Dong Y, Sui L, Watanabe Y, Sugimoto K, Tokuda M. Survivin expression in laryngeal squamous cell carcinomas and its prognostic implications. Anticancer Res 2002;22: 2377-2384.
10. Muzio LL, Pannone G, Staibano S, et al. Survivin expression in oral squamous cell carcinoma. Br J Cancer 2003;89:2244-2248.
11. Muzio LL, Farina A, Rubini C, et al. Survivin as prognostic factor in squamous cell carcinoma of the oral cavity. Cancer Lett 2005;225:27-33.
12. Chang JT, Wong FH, Liao CT, Chen IH, Wang HM, Cheng AJ. Enzyme immunoassay for serum autoantibody to survivin and its findings in head-and-neck cancer patients. Clin Chem 2004;50:1261-1264.
13. Rohayem J, Diestelkoetter P, Weigle B, et al. Antibody responses to the tumor-associated inhibitor of apoptosis protein survivin in cancer patients. Cancer Res 2000; 60:1815-1817.
14. Yagihashi A, Asanuma K, Nakamura M, et al. Detection of anti-survivin antibody in gastrointestinal cancer patients. Clin Chem 2001;47:1729-1731.
15. Yagihashi A, Ohmura T, Asanuma K, et al. Detection of autoantibodies to survivin and livin in sera from patients with breast cancer. Clin Chim Acta 2005;362: 125-130.
16. Zhang JY, Casiano CA, Peng XX, Koziol JA, Chan EKL, Tan EM. Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens. Cancer Epidemiol Biomark Prev 2003;12:136-143.
17. Soussi T. p53 antibodies in the sera of patients with various types of cancer. A review. Cancer Res 2000;60:1777-1788.
18. Shimada H, Ochiai T, Nomura F. Titration of serum p53 antibodies in 1085 patients with various types of malignant tumors. Cancer 2003;97:682-689.
19. Schmidt SM, Schag K, Muller MR, et al. Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells. Blood 2003;102:571-576.
20. Megliorino R, Shi FD, Peng XX, et al. Autoimmune response to anti-apoptotic protein survivin and its association with antibodies to p53 and c-myc in cancer detection. Cancer Detect Prev 2005;29:241-248.
21. de Fromentel CC, Soussi T. TP53 tumor suppressor gene: a model for investigating human mutagenesis. Genes Chromosomes Cancer 1992;4:1-15.
22. Gasco M, Crook T. The p53 network in head and neck cancer. Oral Oncol 2003;39:222-231.
23. Hirohashi Y, Torigoe T, Maeda A, et al. An HLA-A24-restricted cytotoxic T lymphocyte epitope of a tumor-associated protein, survivin. Clin Cancer Res 2002;8: 1731-1739.
24. Recker S, Meier A, Holten-Anderson L, Svane IM, Becker JC, Straten PT, Andersen MH. Identification of novel survivin-derived CTL epitopes. Cancer Biol Ther 2004;3:173-179.
25. Recker S, Becker JC, Svane IM, Ralfkaier E, Straten PT, Anderson MH. HLA-B35-restricted immune responses against survivin in cancer patients. Int J Cancer 2004; 108:937-941.
26. Tas F, Duranyildiz D, Argon A, Oguz H, Camlica H, Yasasever V, Topuz E. Serum bcl-2 and survivin levels in melanoma. Melanoma Res 2004;14:543-546.
27. Yasumatsu R, Nakashima T, Azuma K, et al. SCCA1 expression in T-lymphocytes peripheral to cancer cells is associated with the elevation of serum SCC antigen in squamous cell carcinoma of the tongue. Cancer Lett 2001;167:205-213.